Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab ± apatinib with SOX as neoadjuvant therapy in resectable gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400093157Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab, Rivoceranib, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Pathologic complete response (pCR). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400093157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093157.